Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort have?
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort has 207 citations in the OpenAlex counts ScholarIQ stores.
When was Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort published?
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort has 2019 year in the ScholarIQ index.
What is the open-access status of Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort?
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort has green oa status in the ScholarIQ index.
What is the DOI of Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort?
The DOI for Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort is on the source record.
What is the PMID of Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort?
The PMID for Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort is on the source record.
What is the OpenAlex record for Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort?
The OpenAlex for Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort is on the source record.